RayzeBio on its $357.6 Million IPO
Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering. Partners Carlos Ramirez, Charlie Kim and Marya Postner led the Cooley team advising RayzeBio.
Neumora Therapeutics on its $250.1 Million IPO
Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital […]
ImmuneOnco Biopharmaceuticals on its HK$319 Million IPO
Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million global initial public offering and listing on the Hong Kong Stock Exchange under stock code 1541. Partners Yiming Liu and Michael Yu led the Cooley team.
Laekna on its HK$791 Million IPO
Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date. Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company. Partners […]
Turnstone Biologics on its $80 Million IPO
Cooley advised Turnstone Biologics, a clinical-stage biotechnology company, on its upsized $80 million initial public offering. Lawyers Div Gupta, Ryan Sansom, Lila Hope, Alexa Smith and Valerie Sapozhnikova led the Cooley team advising Turnstone.
Apogee Therapeutics on its $345.1 Million IPO
Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company. Jefferies, TD Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering. Partners Div Gupta, Charlie Kim and Kristin VanderPas […]
Sagimet Biosciences on its $85 Million IPO
Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million. Goldman Sachs & Co., Cowen and Company and Piper Sandler & Co. acted as joint book-running managers for the offering, while JMP Securities acted as lead manager. Partners John McKenna, […]
ACELYRIN on its $621 Million IPO
Cooley advised ACELYRIN, a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever. Lawyers Chadwick Mills, Charlie Kim and Anitha Anne led the Cooley team.
Structure Therapeutics on its $185.3 Million IPO
Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.
TI Cloud on its HK$559.4 Million IPO
Cooley advised TI Cloud, a cloud-native customer contact solution provider, on its HK$559.4 million ($71.7 million) initial public offering of 43,530,000 shares (subject to an overallotment option to issue an additional 6,529,400 shares), which now trade on the Hong Kong Stock Exchange. Partners Michael Yu and Will Cai led the […]